BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, April 29, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 2004

View Archived Issues

Antares Pharma announces agreement with ProSkelia

Read More

BattellePharma now Ventaira Pharmaceuticals

Read More

Celltech Group achieves milestone in osteoporosis collaboration with Amgen

Read More

Genome Therapeutics and Amgen conclude research agreement

Read More

Pierre Fabre presents protein prenyltransferase inhibitors for cancer and other disorders

Read More

Almirall Prodesfarma identifies new H1 antagonists with good selectivity profile

Read More

Novel orally bioavailable VLA-4 antagonists under study at Elan

Read More

BMS scientists claim Eg5 inhibitors and their use in cancer therapy

Read More

Chiron expands its phase II program for IL-2 in the treatment of lymphoma

Read More

Glycopeptide-cephalosporin conjugates prepared and tested at Theravance

Read More

Sanofi-Synthelabo presents beta3-AR agonists for GI disorders and other uses

Read More

Allergan claims novel alpha2-AR agonists with potential as analgesic agents

Read More

Thios licenses rPSGL-Ig from Wyeth

Read More

Medicure looks back at milestone developments

Read More

Archemix and Nuvelo enter development agreement for ARC-183

Read More

Kemin Pharma develops two new molecules for HCV

Read More

Eloxatin approved for first-line treatment of advanced colorectal cancer

Read More

BioStratum and Novo Nordisk to develop antibodies to laminin-5 for cancer

Read More

Approvable letter for Cipher's fenofibrate formulation

Read More

Phase III R-modafinil program progresses towards Q4 NDA filing

Read More

MPI-176716 produces tumor regression in animal models of ovarian cancer

Read More

Schering-Plough/Pharmacopeia collaborative compound enters clinical trials

Read More

New phase I trial for Traficet-EN

Read More

Phase II trial confirms icatibant utility in hereditary angioedema

Read More

Second pivotal trial of methylnaltrexone for opioid-induced constipation

Read More

Namenda available for moderate to severe Alzheimer's disease

Read More

Significant improvements reported for tacrolimus ointment in cutaneous lupus erythematosus

Read More

Eszopiclone improves sleep onset, maintenance and quality in patients with chronic insomnia

Read More

Low-dose DHEA supplements improve endocrine parameters in postmenopausal women

Read More

Identification of anthrax lethal factor inhibitors

Read More

Novel class of farnesyltransferase inhibitors synthesized by Abbott

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 28, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 28, 2026
  • Silhouette of head, brain

    Plasticity, properly parsed, provides psychiatric platform

    BioWorld
    If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...
  • Roche identifies new TREM2 agonists

    BioWorld Science
    F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
  • Three red darts on target

    Sun Pharma to acquire Merck spinoff Organon for $11.75B

    BioWorld
    Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing